Actively Recruiting
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
Led by Beijing Tsinghua Chang Gung Hospital · Updated on 2025-04-03
398
Participants Needed
3
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.
CONDITIONS
Official Title
The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 18 years old
- No gender restrictions
- Diagnosed with prediabetes confirmed by 75g oral glucose tolerance test (fasting blood glucose 65 6.1 and < 7 mmol/L; 2-hour serum glucose 65 7.8 and < 11.1 mmol/L) and glycated hemoglobin < 6.5%
- Abnormal lipid metabolism with LDL-c 65 3.4 mmol/L and < 4.9 mmol/L, triglycerides 64 5.6 mmol/L; non-HDL-c 65 4.1 mmol/L and < 5.7 mmol/L, triglycerides 64 5.6 mmol/L
- Willing to voluntarily sign the informed consent form
You will not qualify if you...
- Diagnosed with diabetes
- Experienced acute coronary syndrome, stroke, or transient ischemic attack within 3 months prior to consent
- ALT or AST levels greater than 3 times the upper limit of normal
- Known myopathy, rhabdomyolysis, or creatine kinase levels more than 4 times the upper limit of normal not caused by muscle injury
- Pregnant or planning to conceive
- Used any lipid-lowering drugs within the past 3 months
- Allergic or contraindicated to Xuezhikang or Atorvastatin
- Suffering from uncontrolled hyperthyroidism or hypothyroidism, severe heart failure, malignant tumors, blood disorders, digestive diseases affecting absorption, mental disorders, or other serious unstable physical diseases
- History of alcohol or drug abuse or dependence within 3 months before joining the trial
- Participated in other clinical drug or device trials within 3 months prior to joining
- Considered unsuitable for participation by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Beiqijia Community Health Service Center, Changping District, Beijing
Beijing, Beijing Municipality, China, 102209
Actively Recruiting
2
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China, 102218
Actively Recruiting
3
Xiaotangshan Community Health Service Center, Changping District, Beijing
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
L
lixia jin, phD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here